In a meta-analysis of 4 placebo-controlled RCTs (2,523 adults with bronchiectasis), DPP-1 inhibitors reduced the risk of an exacerbation (RR 0.64) and severe exacerbations (RR 0.44) and delayed the first (HR 0.66); FEV1 did not differ.
Meta-analysisn = 2,523
Emara et al. Efficacy and safety of DPP-1 inhibitors in bronchiectasis: a GRADE-assessed meta-analysis of randomized controlled trials